[Effect of the pessary treatment on anxiety disorder in patients with symptomatic pelvic organ prolapse].

Objective: To evaluate the effect of the pessary treatment on general anxiety disorder in patients with symptomatic pelvic organ prolapse (POP). Methods: Between December 2018 and January 2020, 213 patients who received the pessary treatment for symptomatic POP in the Peking Union Medical College Hospital (PUMCH) were enrolled in this prospective observational study. Accepting the pessary successfully means that the patient keeping the pessary for 2 weeks were satisfied with it and willing to use it afterwards, or means that the patient having changed a new pessary and keeping it for 2 weeks were satisfied with it and willing to use it afterwards. The questionnaire General Anxiety Disorder-7 (GAD-7) was used to assess the anxiety state of POP patients, including 163 patients who accepted the pessary treatment successfully and 50 patients who failed, before and after the pessary treatment. A score of 10 or more was considered as the moderate or severe anxiety and defined as the anxiety disorder. Patients who accepted the pessary treatment successfully were followed up for 3 months. Results: Before the treatment, the prevalence of anxiety disorders was 20.9% (34 out of 163) for those patients accepting the pessary and that was 20.0% (10 out of 50) for those patients who failed in keeping the pessary, the difference of which were not statistically significant (P=0.896). The difference of demographic data and clinical characteristics between the anxiety disorder group and the non-anxiety disorder group were not statistically significant (P>0.05). After 3 months of the pessary treatment for those patients using the pessary treatment, the prevalence of anxiety disorders dropped to 3.7% (6/163) from 20.9% (P<0.001). The GAD-7 score of patients with anxiety disorders decreased from a median of 16.0 (12.5, 21.0) before the treatment to 1.0 (0, 4.0) after the treatment, and the difference was statistically significant (P<0.001). Conclusion: Around 20% POP patients receiving pessary treatment had the moderate or severe general anxiety disorder. After 3 months of using the pessary treatment, the prevalence of anxiety disorders in POP patients had dropped significantly.

Opa interacting protein 5 promotes metastasis of nasopharyngeal carcinoma cells by promoting EMT via modulation of JAK2/STAT3 signal.

OBJECTIVE: Opa interacting protein 5 (OIP5), as a tumor promoter gene, has emerged as a regulator in several types of tumors. However, the role of OIP5 in nasopharyngeal carcinoma (NPC) has not been reported. In this study, we aimed to explore the expression and biological function of OIP5 in NPC. PATIENTS AND METHODS: The lung cancer datasets GSE12452 and GSE53819 were downloaded from the Gene Expression Omnibus (GEO) repository. Real-time-Polymerase Chain Reaction (RT-PCR) was performed to detect the expression levels of OIP5 mRNA. Cell Counting Kit-8 (CCK-8), colony-formation assay, wound healing assay and transwell assay were conducted to measure cells' proliferation, migration and invasion. Flow cytometry was used for analysis of apoptosis. Western blot assays were used to assess the effects of OIP5 on EMT and JAK2/STAT3 pathway. RESULTS: The up-regulation of OIP5 mRNA was observed in NPC tissues from both GSE12452 and GSE53819. The results of RT-PCR also showed that the expression of OIP5 mRNA was significantly up-regulated in several NPC cell lines compared to normal nasopharyngeal cells. Furthermore, lost-function assay revealed that the knockdown of OIP5 markedly suppressed NPC cells proliferation, migration and invasion, and promoted cell apoptosis. In addition, the results of Western blot showed that silencing of OIP5 suppressed the EMT in NPC cell line. Meanwhile, the knockdown of OIP5 remarkably decreased the expression of p-JAK2 and p-STAT3 protein in both CNE1 and SUNE1 cells. CONCLUSIONS: Our data indicated that OIP5 was highly expressed in NPC and promoted NPC progression by modulating JAK2/STAT3; our results shed light on utilizing OIP5 as a potential novel therapeutic target for the treatment of NPC.

MircoRNA-629 promotes proliferation, invasion and migration of nasopharyngeal carcinoma through targeting PDCD4.

OBJECTIVE: MicroRNAs (miRNA) have been demonstrated to be involved in the development and progression of several tumors, including nasopharyngeal carcinoma (NPC). However, the expression and function of miR-629 in NPC have not been elucidated before. Here, we explored the role of miR-629 in NPC cells and investigated the possible underlying mechanism. MATERIALS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was first utilized to detect the expression of miR-629 in NPC tissues and adjacent normal samples, as well as NPC cell lines and normal nasopharyngeal cell line NP69. MiR-629 mimics and inhibitor was transfected in NPC cells to up-regulate or down-regulate the expression of miR-629. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay and flow cytometry were used to explore the effects of miR-629 on the proliferation and cell circle of established NPC cells, respectively. Cell invasion and migration abilities were evaluated by transwell Matrigel assay and wound healing assay. Meanwhile, the underlying mechanism of miR-629 in NPC was detected using bioinformatics prediction and dual-luciferase analysis. In addition, Western blotting was employed to identify the expression of the miR-629 targeted protein. RESULTS: MiR-629 expression in NPC tissues was significantly higher than that of adjacent normal samples. Expression of miR-629 in NPC cells was significantly higher than that NP69 cells. Over-expressing miR-629 remarkably promoted 6-10B cell proliferation, while knocking down miR-629 significantly inhibited 5-8F cell growth compared with negative control group. Cell migration and invasion abilities were remarkably increased by miR-629 mimics transfection. However, the miR-629 inhibitor transfection in cells significantly decreased cell migration and invasion. Furthermore, dual-luciferase analysis verified that PDCD4 was a direct target gene of miR-629 in NPC cells. Knockdown of PDCD4 in cells over-expressing miR-629 restored cell proliferation and metastasis. CONCLUSIONS: In this study, the expression level of miR-629 was significantly increased in 83 NPC tissues and 4 cell lines. MiR-629 promoted NPC cell growth, migration, and invasion via repressing PDCD4 expression, which might provide a novel target for the future biotherapy for NPC.